{"id":"W4309017087","doi":"10.1093/neuonc/noac209.769","title":"NCOG-16. REAL-WORLD ANALYSIS OF OUTCOMES OF PATIENTS RECEIVING BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA","year":2022,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Bevacizumab; Medicine; Temozolomide; Demographics; Glioblastoma; Oncology; Internal medicine; Progression-free survival; Overall survival; Surgery; Chemotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001803099,0.0003016004,0.0006307212,0.001958182,0.0003622736,0.001047884,0.0006196567,0.0003309365,0.001671659],"category_scores_gemma":[0.006334469,0.000189246,0.0005568537,0.004117546,0.0003041266,0.0005420855,0.0006486038,0.000431947,0.000391814],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002404165,"about_ca_system_score_gemma":0.001530344,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.04301953,"about_ca_topic_score_gemma":0.05822523,"domain_scores_codex":[0.9984333,0.0004562136,0.0003207698,0.0002693577,0.0003171837,0.0002031848],"domain_scores_gemma":[0.9909931,0.0008824027,0.005842734,0.0002966129,0.0009735874,0.001011602],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0007194583,0.00002822321,0.996259,0.00003886199,0.0001132608,0.0000227043,0.00002292422,0.0001401206,0.0000483977,0.00001679176,0.0007885071,0.001801895],"study_design_scores_gemma":[0.00005532898,0.0001607211,0.9976452,0.0000204174,0.00007568952,0.0001230643,0.00009139691,0.0006964413,0.00005529015,0.00003188479,0.001034667,0.000009784808],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9783953,0.0005891207,0.0001499549,0.0001285037,0.00002043456,0.00006824641,0.01944425,0.00002598256,0.001178089],"genre_scores_gemma":[0.9774695,0.000167491,0.0003248105,0.00005955319,0.00002130335,0.0001545523,0.0214456,0.00001397963,0.0003431444],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04301953,"threshold_uncertainty_score":0.08553827,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02366096935636786,"score_gpt":0.3273901123684455,"score_spread":0.3037291430120777,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}